NVIDIA CEO Returns to Korea for Robotics Push as ING Names Korea Pharma Asia's Second Innovation Engine

The Quick Take

• NVIDIA CEO Jensen Huang is returning to Korea for a second major meeting with SK, LG, and Naver leaders to discuss Physical AI and robotics collaboration.
• ING Research named Korea's pharma-bio sector as Asia's second innovation engine after China, though clinical trial speed and new drug approvals remain challenges.
• The dual NVIDIA robotics ecosystem push and ING pharma recognition reinforce Korea's positioning as a high-value AI and healthcare investment destination in Asia.

Jensen Huang's second visit to Korea within seven months marks an escalation in NVIDIA's Korean ecosystem strategy beyond semiconductors into physical AI and robotics. The agenda — meetings with SK Group's Chey Tae-won, LG Group's Koo Kwang-mo, and Naver's Lee Hae-jin — spans Korea's semiconductor supply chain, EV manufacturing, and AI software platform sectors, building a comprehensive robotics hardware and software partnership canvas. Huang's comment at the Taiwan GTC event that robotics is critical underscores why Korea, with its industrial conglomerates and existing chipmaker ties, is NVIDIA's preferred Physical AI partner in Asia.

NVIDIA's deepening Korea engagement is constructive for Samsung Electronics and SK Hynix in HBM memory, Hyundai Motor in robotics integration, and Naver in AI software platforms. The robotics-focused second meeting suggests NVIDIA sees Korea as a critical partner for its Jetson and Isaac robotics platforms, generating incremental revenue beyond the GPU AI training market that has dominated recent NVIDIA-Korea discussions. An explicit NVIDIA robotics partnership from this visit would be a significant re-rating catalyst for the Korean conglomerates involved, as the physical AI market represents a multi-decade growth vector beyond data centre spending.

Watch for any partnership announcements or MOU signings following Huang's June 5-6 visit, which would be the tangible output converting relationship-building into commercial commitments. The ING pharma-bio recognition adds a separate but complementary growth signal — investors should monitor Korea FDA regulatory speed improvements and new drug approval pipeline velocity in 2026. Together, the AI hardware ecosystem deepening and pharma innovation upgrade make Korea a high-conviction Asian growth story if execution follows the signalling from both NVIDIA's visit and ING's sector assessment.

Synthesized from 2 sources.